Cargando…
Integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large B-cell lymphoma
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558790/ https://www.ncbi.nlm.nih.gov/pubmed/34733463 http://dx.doi.org/10.1177/20406207211053120 |
| _version_ | 1784592634167164928 |
|---|---|
| author | Rampotas, Alexandros Sangha, Gina Collins, Graham P. |
| author_facet | Rampotas, Alexandros Sangha, Gina Collins, Graham P. |
| author_sort | Rampotas, Alexandros |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8558790 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | SAGE Publications |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-85587902021-11-02 Integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large B-cell lymphoma Rampotas, Alexandros Sangha, Gina Collins, Graham P. Ther Adv Hematol Editorial SAGE Publications 2021-10-30 /pmc/articles/PMC8558790/ /pubmed/34733463 http://dx.doi.org/10.1177/20406207211053120 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
| spellingShingle | Editorial Rampotas, Alexandros Sangha, Gina Collins, Graham P. Integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large B-cell lymphoma |
| title | Integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large B-cell lymphoma |
| title_full | Integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large B-cell lymphoma |
| title_fullStr | Integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large B-cell lymphoma |
| title_full_unstemmed | Integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large B-cell lymphoma |
| title_short | Integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large B-cell lymphoma |
| title_sort | integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large b-cell lymphoma |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558790/ https://www.ncbi.nlm.nih.gov/pubmed/34733463 http://dx.doi.org/10.1177/20406207211053120 |
| work_keys_str_mv | AT rampotasalexandros integrationofcelltherapiesandbispecificantibodiesintothetreatmentpathwayofrelapseddiffuselargebcelllymphoma AT sanghagina integrationofcelltherapiesandbispecificantibodiesintothetreatmentpathwayofrelapseddiffuselargebcelllymphoma AT collinsgrahamp integrationofcelltherapiesandbispecificantibodiesintothetreatmentpathwayofrelapseddiffuselargebcelllymphoma |